



Current Agreements

Dealdoc

Collaborative R&D agreement for medicines targeting GPCRs

Sosei Heptares
Cubist Pharmaceuticals

Jan 07 2013

Collaborative R&D agreement for medicines targeting GPCRs

Companies:	Sosei Heptares Cubist Pharmaceuticals
Announcement date:	Jan 07 2013
Deal value, US\$m:	9.5 : sum of upfront payment and research funding

- [Details](#)
- [Financials](#)
- [Termsheet](#)
- [Press Release](#)
- [Filing Data](#)
- [Contract](#)

Details

Announcement date:	Jan 07 2013
Industry sectors:	Bigbiotech Pharmaceutical Biotech
Technology types:	Biological compounds Drug delivery » Targeted Small molecules
Deal components:	Collaborative R&D Option
Stages of development:	Discovery
Geographic focus:	Worldwide

Financials

Deal value, US\$m:	9.5 : sum of upfront payment and research funding
Upfront, US\$m:	5.5 : sum of upfront payment
Milestones, US\$m:	n/d : undisclosed n/d : first milestone triggered
Royalty rates, %:	n/d : undisclosed
Funding, US\$m:	4 : sum of research funding

Termsheet

Heptares Therapeutics have signed an agreement with Cubist Pharmaceuticals to collaborate on the research and discovery of new medicines targeting G protein-coupled receptors, which are membrane proteins involved in a broad range of biological processes and diseases.

Under the terms of the agreement, Cubist will receive exclusive worldwide rights to research, develop and commercialize products generated from the collaboration.

The collaborative research will focus on up to two GPCR drug targets to be selected by Cubist.

For the first target, Heptares will receive \$5.5 million (USD) upfront and up to approximately \$4 million in research funding plus milestones and royalties.

Cubist also has the option to nominate a second GPCR target at a later point in the collaboration, which Heptares has agreed to work on according to pre-determined financials.

Further terms of the agreement are not disclosed.

Press Release

22 July 2013

Heptares Achieves First Research Milestone in Research Collaboration With Cubist Pharmaceuticals, Inc. (CBST)

7/22/2013 6:58:48 AM

Heptares Achieves First Research Milestone in Research Collaboration with Cubist

WELWYN GARDEN CITY, England and BOSTON, July 22, 2013-- StaR® Generated to Important GPCR Target Selected by Cubist

Heptares Therapeutics, the leading GPCR drug discovery and development company, announces it has achieved the first research milestone in its collaboration with Cubist Pharmaceuticals, Inc. (CBST), which was announced in January 2013. The milestone is based on the generation of a stabilised (StaR®) form of a GPCR target selected by Cubist, a key step that will enable the structure of the target to be elucidated and a full structure-based drug design (SBDD) programme to be launched.

Cubist will make an undisclosed payment to Heptares as a result of this research milestone being achieved. Under the terms of the agreement, the collaboration is focusing on up to two GPCR drug targets to be selected by Cubist. Heptares has already received US\$5.5 million upfront for the first target, and is eligible to receive up to approximately US\$4 million in research funding plus milestones and royalties. Cubist also has the option to nominate a second GPCR target at a later point in the collaboration, which Heptares has agreed to work on according to pre-determined financials. Further terms of the agreement are not disclosed.

To date, Heptares has achieved all scientific milestones in its collaborations on or ahead of schedule, highlighting the power of its GPCR-focused platform. The structural information that Heptares can routinely access for a range of validated drug targets is being used to advance SBDD programmes and to develop lead candidates in multiple disease indications both in house and with partners.

About Heptares Therapeutics

Heptares creates new medicines targeting clinically important, yet historically challenging, GPCRs (G protein-coupled receptors), a superfamily of drug receptors linked to a wide range of human diseases. Leveraging our advanced structure-based drug design technology platform, we have built an exciting discovery and development pipeline of novel drug candidates, which have the potential to transform the treatment of serious diseases, including Alzheimer's disease, Parkinson's disease, schizophrenia, migraine and diabetes. Our pharmaceutical partners include Shire, AstraZeneca, MedImmune, Morphosys, Takeda and Cubist, and we are backed by Clarus Ventures, MVM Life Science Partners, Novartis Venture Fund, the Stanley Family Foundation and Takeda Ventures. To learn more about Heptares, please visit <http://www.heptares.com>

About G protein-coupled receptors (GPCRs)

The GPCR superfamily is the largest and single most important family of drug targets in the human body. It plays a central role in many biological processes and is linked to a wide range of disease areas. GPCRs are expressed in every type of cell in the body where their function is to transmit signals from outside the cell across the membrane to signaling pathways within the cell, between cells and between organ systems. There are over 375 GPCRs encoded in the human genome, of which 225 have known ligands and 150 are orphan targets. GPCRs are the site of action of 25-30% of current drugs. Six of the top ten and 60 of the top 200 best-selling drugs in the US in 2010 target GPCRs.

7 January 2013

Heptares Partners with Cubist to Research New Medicines Targeting GPCRs By Heptares Therapeutics

WELWYN GARDEN CITY, England and BOSTON, January 7, 2013

Heptares Therapeutics, the leading GPCR drug discovery and development company, today announced they have signed an agreement with Cubist Pharmaceuticals, Inc. (Nasdaq: CBST) to collaborate on the research and discovery of new medicines targeting G protein-coupled receptors (GPCRs), which are membrane proteins involved in a broad range of biological processes and diseases.

Under the terms of the agreement, Cubist will receive exclusive worldwide rights to research, develop and commercialize products generated from the collaboration. The collaborative research will focus on up to two GPCR drug targets to be selected by Cubist. For the first target, Heptares will receive \$5.5 million (USD) upfront and up to approximately \$4 million in research funding plus milestones and royalties. Cubist also has the option to nominate a second GPCR target at a later point in the collaboration, which Heptares has agreed to work on according to pre-determined financials. Further terms of the agreement are not disclosed.

Steve Gilman, Cubist Executive Vice President, Research & Development and Chief Scientific Officer said: "We are pleased to collaborate with Heptares, a recognized leader in the GPCR field, to pursue potential new GPCR drug candidates. This partnership underscores our commitment to develop a robust pipeline of novel products that address high unmet medical needs in patients with acute diseases."

"We are very excited to work with Cubist, one of the fastest growing biopharmaceutical companies in the world and a commercial leader in the acute care therapeutics area," said Malcolm Weir, CEO of Heptares. "This agreement further demonstrates the strength of our strategy to extend the reach of our unique platform across the GPCR universe through partnerships with leading pharmaceutical and specialty companies, while advancing our own proprietary pipeline into clinical development."

About G protein-coupled receptors (GPCRs)

The GPCR superfamily is the largest and single most important family of drug targets in the human body. It plays a central role in many biological processes and is linked to a wide range of disease areas. GPCRs are expressed in every type of cell in the body where their function is to transmit signals from outside the cell across the membrane to signaling pathways within the cell, between cells and between organ systems. There are over 375 GPCRs encoded in the human genome, of which 225 have known ligands and 150 are orphan targets. GPCRs are the site of action of 25-30% of current drugs. Six of the top ten and 60 of the top 200 best-selling drugs in the US in 2010 target GPCRs.

About Heptares Therapeutics

Heptares creates new medicines targeting clinically important, yet historically challenging, GPCRs (G protein-coupled receptors), a superfamily of drug receptors linked to a wide range of human diseases. Leveraging our advanced structure-based drug design technology platform, we have built an exciting discovery and development pipeline of novel drug candidates, which have the potential to transform the treatment of serious diseases, including Alzheimer's disease, Parkinson's disease, schizophrenia, migraine and diabetes. Our pharmaceutical partners include Shire, AstraZeneca, MedImmune, Takeda and Cubist, and we are backed by MVM Life Science Partners, Clarus Ventures, Novartis Venture Fund and Takeda Ventures. To learn more about Heptares, please visit <http://www.heptares.com>.

Filing Data

Not available.

Contract

Not available.